Description:
The investigators evaluated the incidence of BRCA loss in patients with advanced gastric
cancer and observed the treatment outcome and prognosis according to BRCA loss. And the
investigators evaluated the possibility of BRCA loss as a predictive and prognostic factor.
Title
- Brief Title: BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer
- Official Title: A Pilot Trial of Platinum Based Chemotherapy According to BRCA Expressions as First-line Chemotherapy in Patients With Metastatic Gastric Cancer
Clinical Trial IDs
- ORG STUDY ID:
1771-001-287
- NCT ID:
NCT03838406
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Chemotherapy | FOLFOX or CAPOX | BRCA1 negative |
Purpose
The investigators evaluated the incidence of BRCA loss in patients with advanced gastric
cancer and observed the treatment outcome and prognosis according to BRCA loss. And the
investigators evaluated the possibility of BRCA loss as a predictive and prognostic factor.
Detailed Description
Stomach cancer is still the leading cause of cancer deaths globally and is reported to be the
second leading cause of cancer deaths in Korea (18.7%). Although the number of radical
resection has increased due to the development of early diagnosis, many patients experience
recurrence after radical resection. It is also diagnosed as a non - resectable disease
locally advanced at the time of initial diagnosis, or with a metastasis. In patients with
recurrent / metastatic gastric cancer, conventional palliative chemotherapy is the best
treatment, and in advanced gastric cancer, combination therapy with fluoropyrimidine
(fluorouracil, capecitabine, S1) and platinum (oxaliplatin, cisplatin). The progression-free
survival was 3-5 months, and overall survival of 6-10 months in metastatic gastric cancer
patients.
The investigators evaluated the incidence of BRCA loss in patients with advanced gastric
cancer and observed the treatment outcome and prognosis according to BRCA loss. And the
investigators evaluated the possibility of BRCA loss as a predictive and prognostic factor.
Trial Arms
Name | Type | Description | Interventions |
---|
BRCA1 positive | Experimental | FOLFOX or CAPOX Chemotherapy
FOLFOX :
Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.
CAPOX:
Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days. | |
BRCA1 negative | Active Comparator | FOLFOX or CAPOX Chemotherapy
FOLFOX :
Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + 5-FU 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.
CAPOX:
Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days. | |
Eligibility Criteria
Inclusion Criteria:
- Metastatic gastric cancer( Adenocarcinoma)
- Eastern Cooperative Oncology Group (ECOG) performance 0-2
- one more measure lesion
- White blood cell count (WBC) > 3000/ul , Platelet > 75,000/ul
- Normal kidney function (serum creatinine < 1.5 ULN)
- Normal Liver function (Aspartate aminotransferase (AST)/ Alanine aminotransferase
(ALT) < 3 times of upper normal limit, if liver metastasis, AST/ALT < 5 times of upper
normal limit)
- life expectancy is more than 3 months
- Conventional surgery that does not cause the transformation of the target lesion is
allowed
- The patient who voluntarily decided to participate in this study and agreed in writing
Exclusion Criteria:
- Her-2 positive advanced gastric cancer
- Central nervous system metastases requiring treatment with symptoms
- Major uncontrolled cardiovascular disease (including myocardial infarction and
congestive heart failure within 6 months)
- Uncontrolled infection or other serious diseases
- Patients with serious medical conditions or serious illnesses
- Patient who is pregnant or lactating
- Adjuvant chemotherapy before 6 months (patients who have not received platinum-based
chemotherapy even if they are 6 months old can register)
- In the past, if the primary lesion or target lesion was treated with radiation (if the
recurred lesion is outside the range of radiation therapy)
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 19 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Objective response rate |
Time Frame: | through study completion, an average of 1 year |
Safety Issue: | |
Description: | the proportion of patients who have a partial or complete response to therapy; it does not include stable disease and is a direct measure of drug tumoricidal activity. |
Secondary Outcome Measures
Measure: | Progression free survival |
Time Frame: | through study completion, an average of 1 year |
Safety Issue: | |
Description: | the time from diagnosis to death by any cause and progression. |
Measure: | Overall survival |
Time Frame: | through study completion, an average of 1 year |
Safety Issue: | |
Description: | the time from diagnosis to death by any cause |
Details
Phase: | N/A |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | Chung-Ang University |
Trial Keywords
- Stomach cancer
- Chemotherapy
- FOLFOX
- Capecitabine plus Oxalipatin (CAPOX)
Last Updated
January 27, 2021